Vera Therapeutics

Our Science

Pipeline

Program
Indication
Phase 1
Phase 2
Phase 3
Next
Milestone
Global
Rights

Fusion protein that blocks BLyS and APRIL

IgAN

Ph 2b primary endpoint early Q1 2023

Origin Logo
Vera Therapeutics
Lupus Nephritis

Ph 3 primary endpoint
2026

Vera Therapeutics

Monoclonal antibody that neutralizes BK virus

BK Viremia in Renal
Transplant

Ph 2b or Ph 3 trial initiation 2023

Vera Therapeutics
BKV Cystitis in Hematopoetic Stem Cell Transplant (HSCT)
Under Exploration

Undisclosed

Vera Therapeutics

At Vera, we believe in changing standard of care for patients living with immunologic disease around the world. Collaborations are an essential part of this commitment, reach out to us at bd@veratx.com to discuss potential partnering opportunities.

Top